These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 19060844)

  • 1. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.
    Clarke B; Tinker AV; Lee CH; Subramanian S; van de Rijn M; Turbin D; Kalloger S; Han G; Ceballos K; Cadungog MG; Huntsman DG; Coukos G; Gilks CB
    Mod Pathol; 2009 Mar; 22(3):393-402. PubMed ID: 19060844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes.
    Stumpf M; Hasenburg A; Riener MO; Jütting U; Wang C; Shen Y; Orlowska-Volk M; Fisch P; Wang Z; Gitsch G; Werner M; Lassmann S
    Br J Cancer; 2009 Nov; 101(9):1513-21. PubMed ID: 19861998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
    Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
    Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.
    Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
    Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression.
    Liu M; Matsumura N; Mandai M; Li K; Yagi H; Baba T; Suzuki A; Hamanishi J; Fukuhara K; Konishi I
    Mod Pathol; 2009 Mar; 22(3):373-84. PubMed ID: 18997734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
    Sato E; Olson SH; Ahn J; Bundy B; Nishikawa H; Qian F; Jungbluth AA; Frosina D; Gnjatic S; Ambrosone C; Kepner J; Odunsi T; Ritter G; Lele S; Chen YT; Ohtani H; Old LJ; Odunsi K
    Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18538-43. PubMed ID: 16344461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma.
    Saner FAM; Takahashi K; Budden T; Pandey A; Ariyaratne D; Zwimpfer TA; Meagher NS; Fereday S; Twomey L; Pishas KI; Hoang T; Bolithon A; Traficante N; ; Alsop K; Christie EL; Kang EY; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Alsop J; Beckmann MW; Boros J; Brand AH; Brooks-Wilson A; Carney ME; Coulson P; Courtney-Brooks M; Cushing-Haugen KL; Cybulski C; El-Bahrawy MA; Elishaev E; Erber R; Gayther SA; Gentry-Maharaj A; Gilks CB; Harnett PR; Harris HR; Hartmann A; Hein A; Hendley J; Hernandez BY; Jakubowska A; Jimenez-Linan M; Jones ME; Kaufmann SH; Kennedy CJ; Kluz T; Koziak JM; Kristjansdottir B; Le ND; Lener M; Lester J; Lubiński J; Mateoiu C; Orsulic S; Ruebner M; Schoemaker MJ; Shah M; Sharma R; Sherman ME; Shvetsov YB; Soong TR; Steed H; Sukumvanich P; Talhouk A; Taylor SE; Vierkant RA; Wang C; Widschwendter M; Wilkens LR; Winham SJ; Anglesio MS; Berchuck A; Brenton JD; Campbell I; Cook LS; Doherty JA; Fasching PA; Fortner RT; Goodman MT; Gronwald J; Huntsman DG; Karlan BY; Kelemen LE; Menon U; Modugno F; Pharoah PDP; Schildkraut JM; Sundfeldt K; Swerdlow AJ; Goode EL; DeFazio A; Köbel M; Ramus SJ; Bowtell DDL; Garsed DW
    Clin Cancer Res; 2024 Aug; 30(16):3481-3498. PubMed ID: 38837893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
    Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
    Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic markers of inflammation in endometrioid and clear cell ovarian cancer.
    Gallego A; Mendiola M; Hernando B; Berjon A; Cadiz A; Chaves-Urbano B; Heredia-Soto V; Spagnolo E; Hernández Gutiérrez A; Hardisson D; Macintyre G; Redondo A; Garcia MJ
    Int J Gynecol Cancer; 2022 Aug; 32(8):1009-1016. PubMed ID: 35437272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer.
    Adams SF; Levine DA; Cadungog MG; Hammond R; Facciabene A; Olvera N; Rubin SC; Boyd J; Gimotty PA; Coukos G
    Cancer; 2009 Jul; 115(13):2891-902. PubMed ID: 19472394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
    Pinto MP; Balmaceda C; Bravo ML; Kato S; Villarroel A; Owen GI; Roa JC; Cuello MA; Ibañez C
    Gynecol Oncol; 2018 Oct; 151(1):10-17. PubMed ID: 30078505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.
    Leffers N; Gooden MJ; de Jong RA; Hoogeboom BN; ten Hoor KA; Hollema H; Boezen HM; van der Zee AG; Daemen T; Nijman HW
    Cancer Immunol Immunother; 2009 Mar; 58(3):449-59. PubMed ID: 18791714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
    ; Goode EL; Block MS; Kalli KR; Vierkant RA; Chen W; Fogarty ZC; Gentry-Maharaj A; Tołoczko A; Hein A; Bouligny AL; Jensen A; Osorio A; Hartkopf A; Ryan A; Chudecka-Głaz A; Magliocco AM; Hartmann A; Jung AY; Gao B; Hernandez BY; Fridley BL; McCauley BM; Kennedy CJ; Wang C; Karpinskyj C; de Sousa CB; Tiezzi DG; Wachter DL; Herpel E; Taran FA; Modugno F; Nelson G; Lubiński J; Menkiszak J; Alsop J; Lester J; García-Donas J; Nation J; Hung J; Palacios J; Rothstein JH; Kelley JL; de Andrade JM; Robles-Díaz L; Intermaggio MP; Widschwendter M; Beckmann MW; Ruebner M; Jimenez-Linan M; Singh N; Oszurek O; Harnett PR; Rambau PF; Sinn P; Wagner P; Ghatage P; Sharma R; Edwards RP; Ness RB; Orsulic S; Brucker SY; Johnatty SE; Longacre TA; Ursula E; McGuire V; Sieh W; Natanzon Y; Li Z; Whittemore AS; Anna A; Staebler A; Karlan BY; Gilks B; Bowtell DD; Høgdall E; Candido dos Reis FJ; Steed H; Campbell IG; Gronwald J; Benítez J; Koziak JM; Chang-Claude J; Moysich KB; Kelemen LE; Cook LS; Goodman MT; García MJ; Fasching PA; Kommoss S; Deen S; Kjaer SK; Menon U; Brenton JD; Pharoah PDP; Chenevix-Trench G; Huntsman DG; Winham SJ; Köbel M; Ramus SJ
    JAMA Oncol; 2017 Dec; 3(12):e173290. PubMed ID: 29049607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse.
    Hollis RL; Carmichael J; Meynert AM; Churchman M; Hallas-Potts A; Rye T; MacKean M; Nussey F; Semple CA; Herrington CS; Gourley C
    Am J Obstet Gynecol; 2019 Sep; 221(3):245.e1-245.e15. PubMed ID: 31055034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma.
    Hagemann AR; Hagemann IS; Cadungog M; Hwang WT; Patel P; Lal P; Hammond R; Gimotty PA; Chu CS; Rubin SC; Birrer MJ; Powell DJ; Feldman MD; Coukos G
    Cancer Biol Ther; 2011 Aug; 12(4):367-77. PubMed ID: 21785280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium.
    Bachmayr-Heyda A; Aust S; Heinze G; Polterauer S; Grimm C; Braicu EI; Sehouli J; Lambrechts S; Vergote I; Mahner S; Pils D; Schuster E; Thalhammer T; Horvat R; Denkert C; Zeillinger R; Castillo-Tong DC
    BMC Cancer; 2013 Sep; 13():422. PubMed ID: 24044611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma-A Study by the Spanish Group for Ovarian Cancer Research (GEICO).
    Pizarro D; Romero I; Pérez-Mies B; Redondo A; Caniego-Casas T; Carretero-Barrio I; Cristóbal E; Gutiérrez-Pecharromán A; Santaballa A; D'Angelo E; Hardisson D; Vieites B; Matías-Guiu X; Estévez P; Guerra E; Prat J; Poveda A; López-Guerrero JA; Palacios J
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8
    Park J; Kim JC; Lee YJ; Kim S; Kim SW; Shin EC; Lee JY; Park SH
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 38964784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.